Stock ASLN ASLAN PHARMACEUTICALS LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases ASLAN Pharmaceuticals Limited

Equities

ASLN

US04522R2004

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-29 pm EDT 		5-day change 1st Jan Change
0.457 USD +10.04% Intraday chart for ASLAN Pharmaceuticals Limited +0.44% -12.47%
Apr. 29 Asian Equities Traded in the US as American Depositary Receipts Open Week on Flat Note in Monday Trading MT
Apr. 26 Asian Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading, End Week Up 3.5% MT

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
ASLAN Pharmaceuticals Announces Late Breaking Abstract on Eblasakimab in COPD Accepted for Presentation at the American Thoracic Society International Conference
AQ
ASLAN Pharmaceuticals Announces Receipt of Nasdaq Notice - April 19, 2024
AQ
ASLAN Pharmaceuticals Announces Positive Interim Results From Phase 2 Study of Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients
AQ
ASLAN PHARMACEUTICALS : ANNOUNCES POSITIVE INTERIM RESULTS FROM PHASE 2 STUDY OF EBLASAKIMAB IN DUPILUMAB-EXPERIENCED ATOPIC DERMATITIS PATIENTS - Form 6-K
PU
ASLAN Pharmaceuticals Announces Receipt of Nasdaq Notice
AQ
ASLAN PHARMACEUTICALS : ANNOUNCES RECEIPT OF NASDAQ NOTICE - Form 6-K
PU
ASLAN Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and provides corporate update
AQ
ASLAN Pharmaceuticals : AMENDMENT NO. 2 TO THE OPEN MARKET SALE AGREEMENTSM - Form 6-K
PU
ASLAN Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
AQ
ASLAN PHARMACEUTICALS : REPORTS FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE - Form 6-K
PU
ASLAN Pharmaceuticals : H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference
PU
Aslan Pharmaceuticals to Present at the 2nd Annual H.C. Wainwright Autoimmune and Inflammatory Disease Virtual Conference: Skin Diseases, Conditions and Disorders
AQ
ASLAN Pharmaceuticals Announces $5 Million Registered Direct Offering
AQ
ASLAN Pharmaceuticals Provides TREK-DX Study Update and Highlights Potential of Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients
AQ
ASLAN Pharmaceuticals Announces New Translational Data on Eblasakimab in COPD and Appoints Leading Respiratory Experts as Scientific Advisors
AQ
ASLAN Pharmaceuticals Receives Favorable Opinion From the European Patent Office on Composition of Matter Patent Application for Farudodstat
AQ
ASLAN Pharmaceuticals Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement
AQ
ASLAN Pharmaceuticals Announces Participation in January Investor Conferences
AQ
ASLAN Pharmaceuticals ( "") Form 6 : ASLAN Pharmaceuticals Limited (the "Company") - Form 6-K
PU
ASLAN Pharmaceuticals Provides Year-End Update on Its Eblasakimab and Farudodstat Programs
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ASLN Stock
  4. News ASLAN Pharmaceuticals Limited
  5. Press Releases